SG Americas Securities LLC Has $831,000 Stock Holdings in Insulet Corporation $PODD

SG Americas Securities LLC trimmed its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 91.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,691 shares of the medical instruments supplier’s stock after selling 27,923 shares during the quarter. SG Americas Securities LLC’s holdings in Insulet were worth $831,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. True Wealth Design LLC grew its stake in shares of Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 72 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 69 shares during the period. Trust Co. of Toledo NA OH acquired a new position in Insulet during the 2nd quarter worth about $35,000. Osterweis Capital Management Inc. bought a new stake in shares of Insulet in the 2nd quarter valued at about $51,000. Finally, NewEdge Advisors LLC increased its stake in shares of Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after buying an additional 64 shares during the period.

Insulet Stock Down 1.2%

Shares of NASDAQ PODD opened at $284.25 on Wednesday. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. The firm has a market cap of $20.00 billion, a PE ratio of 82.39, a P/E/G ratio of 1.60 and a beta of 1.40. The company’s fifty day simple moving average is $301.80 and its 200 day simple moving average is $310.75. Insulet Corporation has a 12-month low of $230.05 and a 12-month high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The business’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.08 earnings per share. As a group, sell-side analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of recent analyst reports. Zacks Research lowered Insulet from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Wells Fargo & Company boosted their price target on shares of Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Leerink Partners upped their price objective on shares of Insulet from $385.00 to $386.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Wolfe Research lifted their target price on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Finally, Stifel Nicolaus started coverage on shares of Insulet in a report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 target price on the stock. Twenty-one investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Insulet has an average rating of “Moderate Buy” and an average target price of $379.10.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.